<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3818">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01328574</url>
  </required_header>
  <id_info>
    <org_study_id>110130</org_study_id>
    <secondary_id>11-C-0130</secondary_id>
    <nct_id>NCT01328574</nct_id>
  </id_info>
  <brief_title>TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma</brief_title>
  <official_title>A Phase II Study of TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background:

      - Urothelial cancer (tumors of the bladder, urethra, ureter, or renal pelvis) often responds
      initially to standard chemotherapy treatments, but frequently recurs and can often spread to
      other parts of the body. TRC105, an experimental drug that blocks the development of the new
      blood vessels needed for tumor growth, may be able to shrink or stabilize urothelial cancer
      tumors. TRC105 has been given previously to individuals with other types of cancer, and
      researchers are interested in determining its safety and effectiveness in treating
      urothelial cancer.

      Objectives:

      - To determine the safety and effectiveness of TRC105 as a treatment for metastatic
      urothelial cancer that has not responded to standard treatments.

      Eligibility:

      - Individuals at least 18 years of age who have been diagnosed with urothelial cancer that
      has spread to other parts of the body and has not responded to standard chemotherapy.

      Design:

        -  Participants will be screened with a physical examination, medical history, blood
           tests, and tumor imaging studies.

        -  Participants will receive TRC105 intravenously once every 2 weeks on days 1 and 15 of a
           28-day treatment cycle. The first dose of TRC105 will be given over a 4-hour period;
           participants who do not have side effects may receive the next dose over 2 hours. If
           the second dose is tolerated, subsequent doses can be given over at least 1 hour.

        -  To help prevent known side effects of TRC105, participants will take two doses (one in
           the morning and one in the evening) of the steroid dexamethasone on the day before each
           infusion is scheduled. Participants may have additional dexamethasone 30 minutes before
           infusion, and may have the infusion slowed or stopped to adjust for side effects.

        -  Participants will be monitored with blood samples, physical examinations, and tumor
           imaging studies through the cycles of treatment.

        -  Participants will continue to take TRC105 for as long as the treatment is effective
           against the cancer and as long as the side effects are not severe enough to stop
           treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BACKGROUND:

        -  In the United States, urothelial carcinoma (UC) of the bladder is the 4th most common
           malignancy in men and the 9th most common in women with an estimated 70,980 new cases
           and 14,330 deaths in the year 2009. Although it is chemosensitive with response
           proportions of over 50% with conventional cytotoxic regimens, the response durations
           are short and the median survival of patients with metastatic disease is approximately
           14 months.

        -  TRC105 is a genetically engineered human/murine chimeric monoclonal antibody that
           inhibits angiogenesis and tumor growth via endothelial cell growth inhibition and
           apoptosis. TRC105 is directed against human CD105 (endoglin), an angiogenic membrane
           protein that is highly expressed on proliferating vasculature in solid tumors and
           up-regulated following anti-VEGF (vascular endothelial growth factor) therapy. Clinical
           studies in bladder cancer with anti-angiogenic agents have shown anti-tumor activity.

        -  TRC105 targets a unique mechanism for tumor angiogenesis, through modification of CD105
           signaling. In patients with advanced bladder cancer that have progressed through
           standard chemotherapy and have no further life prolonging therapeutic options, use of
           this novel angiogenesis inhibitor may improve outcomes.

      OBJECTIVES:

        -  To measure PFS (progression free survival) of TRC105 as determined by RECIST (Response
           Evaluation Criteria in Solid Tumors) v1.1

        -  To determine the safety and toxicity of TRC105 in this patient population.

        -  In addition, in a preliminary fashion, response rate and overall survival of patients
           with metastatic urothelial carcinoma of the bladder treated with TRC105 will be
           estimated.

      ELIGIBILITY:

        -  Adults with progressive advanced/metastatic urothelial carcinoma that have progressed
           despite treatment with prior cytotoxic chemotherapy.

        -  Subjects must have received at least one prior cytotoxic agent (which must have
           included at least one of the following: cisplatin, carboplatin, paclitaxel, docetaxel,
           or gemcitabine).

      DESIGN:

        -  TRC105 will be administered at a dose of 15 mg/kg intravenously every two weeks, on
           days 1 and 15 of each 28 day cycle.

        -  Patients may continue on study as long as they are tolerating therapy and are free of
           disease progression.

        -  The study will be conducted as a two-stage optimal design (Simon 1989). With alpha=0.10
           and beta=0.10 as acceptable error probabilities, the trial will target 30% as the
           desirable proportion of patients who are still without progression by radiographic
           criteria at approximately 6 months (p1=0.30), and will be considered inadequate if only
           a fraction consistent with 10% are without progression by the same evaluation time
           (p0=0.10). Initially 12 patients will be enrolled and followed for progression. If 2 or
           more of the first 12 patients reach 6 months without progression, then enrollment will
           continue until a total of 35 evaluable patients (37 total patients to allow for a small
           number of inevaluable patients) have been entered.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">May 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>after 6 months on study</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of participants who are progression free after 6 months on study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>24 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Urothelial Carcinoma</condition>
  <condition>Ureteral Neoplasms</condition>
  <condition>Ureter Cancer</condition>
  <condition>Neoplasm, Ureteral</condition>
  <condition>Cancer of the Ureter</condition>
  <arm_group>
    <arm_group_label>Single Arm - TRC105 in Urothelial Carcinoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRC105 15 mg/kg/dose every two weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TRC105</intervention_name>
    <description>15 mg/kg intravenously</description>
    <arm_group_label>Single Arm - TRC105 in Urothelial Carcinoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

          -  Patients must have a diagnosis of urothelial carcinoma of the bladder, urethra,
             ureter, or renal pelvis, with histological confirmation at the Laboratory of
             Pathology of the NCI (National Cancer Institute), NIH (National Institutes of
             Health).

          -  Patients must have progressive metastatic disease. Progressive disease will be
             defined as new or progressive lesions on cross-sectional imaging. Patients must have
             at least:

          -  One measurable site of disease (according to RECIST criteria) that has not been
             previously irradiated. If the patient has had previous radiation to the marker
             lesion(s), there must be evidence of progression since the radiation.

          -  Or, appearance of one new bone lesion.

          -  Patients must have been previously treated, as defined by the following:

          -  Treatment with at least one prior cytotoxic agent (which must have included at least
             one of the following: cisplatin, carboplatin, paclitaxel, docetaxel, or gemcitabine),
             administered in the perioperative or metastatic setting and may have been
             administered sequentially (e.g., first-line treatment followed by second-line
             treatment at time of progression) or as part of a single regimen.

          -  18 years of age or older

          -  ECOG (Eastern Cooperative Oncology Group) performance status of &lt; 2 or Karnofsky
             Performance Status greater than or equal to 60%

          -  Resolution of all acute toxic effects of prior chemotherapy, radiotherapy, or
             surgical procedure to NCI CTCAE (Common Terminology Criteria in Adverse Events) grade
             less than or equal to 1 or baseline

          -  Adequate organ function as defined by the following criteria:

          -  Serum aspartate transaminase (AST (Aspartate transaminase); serum glutamic
             oxaloacetic transaminase [SGOT (serum glutamic oxaloacetic)]) and serum alanine
             transaminase (ALT (alanine transaminase); serum glutamic pyruvic transaminase [SGPT
             (serum glutamic pyruvic transaminase)]) less than or equal to 2.5 times the upper
             limit of normal (ULN); 5.0 times the ULN in cases of liver metastases

          -  Total serum bilirubin less than or equal to 1.5 mg/dL (unless elevation from
             Gilbert's disease or similar syndrome due to slow conjugation of bilirubin)

          -  Absolute neutrophil count (ANC) greater than or equal to 1000/microL

          -  Platelets greater than or equal to 100,000/microL

          -  Serum creatinine less than or equal to 2.0 mg/dl or calculated creatinine clearance
             (CrCl) greater than or equal to 30 mL/min

          -  Hemoglobin &gt; 9gm/dL

          -  PT (prothrombin time), aPTT (activated partial thromboplastin time) must be within
             normal range

          -  Patients on anticoagulants may be enrolled as long as the INR (International
             normalized ratio) does not exceed 3.

        EXCLUSION CRITERIA:

          -  Receipt of an investigational agent within 4 weeks prior to first dose with TRC105

          -  Major surgery including open biopsy or systemic therapy &lt; 4 weeks prior to first dose
             with TRC105

          -  Radiation therapy (except small field) &lt; 3 weeks prior to first dose with TRC105

          -  Small field radiation therapy &lt; 2 weeks prior to first dose with TRC105

          -  Minor surgical procedures within 2 weeks

          -  Uncontrolled chronic hypertension (systolic &gt; 140 or diastolic &gt; 90mm Hg despite
             optimal therapy)

          -  Brain metastasis, or leptomeningeal disease because of their poor prognosis and
             because they often develop progressive neurologic dysfunction that would confound the
             evaluation of neurologic and other adverse events.

          -  Unstable angina, MI, symptomatic congestive heart failure, cerebrovascular accident,
             transient ischemic attack, arterial embolism, pulmonary embolism, DVT (deep vein
             thrombosis), PTCA (percutaneous transluminal coronary angioplasty) or CABG (coronary
             artery bypass graft) within the past 6 months

          -  Cardiac arrhythmias of NCI CTCAE grade greater than or equal to 2 within the last
             month

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Known active hepatitis

          -  Hemorrhage within 30 days of dosing or history of persistent gross hematuria

          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
             related illness

          -  History of hypersensitivity reaction to human or mouse antibody products

          -  Pregnancy or breastfeeding. Female patients must be surgically sterile (i.e.:
             hysterectomy) or be postmenopausal, or must agree to use effective contraception
             during the study and for 3 months following last dose of TRC105. All female patients
             of reproductive potential must have a negative pregnancy test (serum) within 7 days
             prior to first dose. Male patients must be surgically sterile or must agree to use
             effective contraception during the study and for 3 months following last dose of
             TRC105. The definition of effective contraception will be based on the judgment of
             the Principal Investigator or a designated associate.

          -  Other severe acute or chronic medical or psychiatric condition, or laboratory
             abnormality that may increase the risk associated with study participation or study
             drug administration, or may interfere with the interpretation of study results, and
             in the judgment of the Investigator would make the patient inappropriate for entry
             into this study

          -  History of peptic ulcer disease, unless a subsequent endoscopy has confirmed complete
             resolution of the ulcer

          -  History of acquired or inherited hypocoagulopathies (bleeding risk), including but
             not limited to hereditary hemorrhagic telangiectasis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea B Apolo, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2011-C-0130.html</url>
    <description>NIH Clinical Center Detailed Web Page</description>
  </link>
  <reference>
    <citation>McCaffrey JA, Hilton S, Mazumdar M, Sadan S, Kelly WK, Scher HI, Bajorin DF. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol. 1997 May;15(5):1853-7.</citation>
    <PMID>9164195</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300. doi: 10.3322/caac.20073. Epub 2010 Jul 7. Erratum in: CA Cancer J Clin. 2011 Mar-Apr;61(2):133-4.</citation>
    <PMID>20610543</PMID>
  </reference>
  <reference>
    <citation>von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM, Conte PF. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000 Sep;18(17):3068-77.</citation>
    <PMID>11001674</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <lastchanged_date>February 13, 2015</lastchanged_date>
  <firstreceived_date>April 1, 2011</firstreceived_date>
  <firstreceived_results_date>February 13, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Institutes of Health Clinical Center (CC)</investigator_affiliation>
    <investigator_full_name>Andrea Apolo, M.D.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Progression-Free Survival</keyword>
  <keyword>Carcinoma of the Bladder</keyword>
  <keyword>Cancer of the Renal Pelvis</keyword>
  <keyword>Ureter Cancer</keyword>
  <keyword>Survival</keyword>
  <keyword>Bladder Cancer</keyword>
  <keyword>Renal Pelvis Cancer</keyword>
  <keyword>Urothelial Cancer</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Ureteral Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm-TRC105 in Urothelial Carcinoma</title>
          <description>TRC 105 every two weeks
TRC105: 15 mg/kg intravenously</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Refused further treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm-TRC105 in Urothelial Carcinoma</title>
          <description>TRC 105 every two weeks
TRC105: 15 mg/kg intravenously</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="63.28" spread="6.64"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival</title>
        <description>Proportion of participants who are progression free after 6 months on study.</description>
        <time_frame>after 6 months on study</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-TRC105 in Urothelial Carcinoma</title>
            <description>TRC 105 every two weeks
TRC105: 15 mg/kg intravenously</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Progression Free Survival</title>
            <description>Proportion of participants who are progression free after 6 months on study.</description>
            <units>Months</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.94" lower_limit="1.81" upper_limit="2.07"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
        <time_frame>24 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Single Arm-TRC105 in Urothelial Carcinoma</title>
            <description>TRC 105 every two weeks
TRC105: 15 mg/kg intravenously</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Participants With Adverse Events</title>
            <description>Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Arm-TRC105 in Urothelial Carcinoma</title>
          <description>TRC 105 every two weeks
TRC105: 15 mg/kg intravenously</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="8" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Floaters</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral hemorrhage</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Creatinine increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypophosphatemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hallucinations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Genital edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Postnasal drip</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Andrea Apolo</name_or_title>
      <organization>National Cancer Institute</organization>
      <phone>301-451-1984</phone>
      <email>apoloab@mail.nih.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
